In contrast to the current recommendations, some recent trials evaluating the effect of early β-blocker treatment failed to demonstrate a decrease of mortality in patients with STEMI (4, 5) . In view of these recent controversies, we analyzed our data of the Lower Austrian Myocardial Infarction network with regard to the effect of immediate vs. delayed β-blocker treatment on mortality of patients with STEMI.
METHODS

Study Design
Patients for this analysis were drawn from the database of the Lower Austrian Myocardial Infarction Network, which included patients presented with the primary diagnosis of a STEMI according to the AHA criteria. As we established the Network, numerous hypothesis were a priori defined and evaluated by the local Ethical Committee. The observation period was a priori defined from June 2006 to December 2010. The treatment protocol of the network was defined prior to the start of data collection and included unambiguous guidelines concerning reperfusion strategies, platelet inhibition, anticoagulation, and concomitant β-blocker therapy (the detailed protocol of the network is described in detail in the following paragraphs). The application of β-blockers was recommended either immediately after diagnosis of a STEMI (defined within the first 30 min after STEMI was confirmed with a 12-lead electrocardiogram [ECG] ) or after 24 hours of the acute event. However, as the final decision depends on the physician on duty, the characteristic of the study is nonrandomized, prospective, and observational. The hypothesis was to evaluate the effect of immediate vs. delayed β-blockade on all-cause mortality of patients with STEMI in our network.
Patient Characteristics
The data of all patients with STEMI diagnosed out-of-hospital by an emergency physician or by a physician in one of the primary-care hospitals between June 1, 2006 , and December 31, 2010, were consecutively collected and retrospectively analyzed. All patients gave their informed consent to use their data for study purposes. The study was approved by the Ethical Committee of the Government of the Federal State of Lower Austria.
Diagnosis and Treatment Protocol
All patients with STEMI diagnosed out-of-hospital or in one of the primary care hospitals within the Lower Austrian Myocardial Infarction Network were included. The network consisted of five emergency medical services (EMS) and five primary care hospitals located in the western part of Lower Austria. The EMS in Austria consisted of a physician with a specific education in emergency medicine and two paramedics. The percutaneous coronary intervention (PCI) center is located in the center of the network and the average distance from the EMS stations to the PCI center was 82 km. STEMI was defined as 1) anterior MI: greater than or equal to 2 mm ST-segment elevation in greater than or equal to 2 of the leads I, aVL, and V1-V6; or 2) inferior MI: greater than or equal to 1 mm ST-segment elevation in greater than or equal to 2 leads II, III, aVF, and V5-V6. The reperfusion strategy depended on the time interval between onset of symptoms and first medical contact. If the time interval was below 120 minutes, a thrombolytic treatment was given and the patient was transferred to the PCI center. In all other cases, patients were transferred directly to primary PCI with a treatment delay of less than 120 minutes from the first medical contact. The diagnosis of a STEMI was assessed by the physician of the EMS or the primary care hospital and confirmed by the cardiologist at the PCI center.
Reperfusion Protocol
Patients without thrombolysis received the following medication given in the ambulance: 250 mg aspirin, 600 mg clopidogrel, a bolus of bivalirudin (0.1 mg/kg), followed by a continuous infusion of bivalirudin (0.25 mg/kg/hr). The emergency physician used this predefined treatment protocol in all patients with STEMI. Patients eligible for thrombolysis received rtPa according to the guidelines, 250 mg aspirin, 300 mg clopidogrel, and weight-adjusted unfractioned heparin.
β-Blockade
The use of bisoprolol (2.5 mg oral) immediately after diagnosis of the STEMI was recommended by protocol. Administration of bisoprolol by the emergency physician either out-of-hospital or in the emergency department of the primary care hospital has to be done within 30 minutes after confirmation of an acute STEMI by the first ECG. Contraindications for the use of bisoprolol were systolic blood pressure less than 100 mm Hg, bradycardia (HR less than 60/min), AV-block II° or III°, and clinical signs of heart failure (rales over both lungs, cyanosis). However, the final decision to give bisoprolol depended on the emergency physician on duty. If the patient did not receive bisoprolol within the first 30 minutes after the primary ECG, the protocol recommended bisoprolol 24 hours after the first ECG. Patients who remained free of any β-blocker treatment were excluded from further analysis, as well as patients who received bisoprolol outlying the defined timing of the protocol.
Management at the PCI Center
After arrival in the emergency department of the PCI center, patients without thrombolytic treatment were transferred immediately to the catheterization suite. Coronary angiography was performed to identify the infarct-related artery. In case of a PCI, either a bolus of bivalirudin was given (0.5 mg/kg) followed by an increase of the continuous infusion (1.75 mg/kg/hr) or a bolus of unfractioned heparin was given (60 IU/kg; maximum dose of 4000 IU) intravenously followed by a continuous infusion of 1000 IU/hr in the emergency service. Additionally, abciximab was administered (dose: bolus: 0.25 mg/kg followed by a continuous infusion [dose: 0.125 μg/kg/min]) until the guide wire was removed.
Outcome Parameters
The primary outcome parameter was all-cause mortality in patients with immediate vs. delayed β-blocker therapy.
Secondary parameters included cardiovascular death 30 days and 1 year after MI. The effect of β-blockers on two predefined subgroups was also investigated: elderly patients aged over 70 years and patients with greater than or equal to two criteria for an increased risk of shock according to current guidelines (1) . Criteria for an increased risk of shock included age greater than 70 years, symptoms greater than 12 hours, systolic blood pressure less than 120 mm Hg, heart rate greater than 110 bpm. Safety parameters were the frequency of congestive heart failure (Killip class III or IV), cardiogenic shock, and bradyarrhythmia with the need of intervention or cardiopulmonaryresuscitation due to ventricular fibrillation within the first 24 hours.
Fatal events were retrieved from the Statistical Department of the Austrian government, which collected the causes of death of all patients who died in a hospital in Austria. Patients who died from noncardiovascular cause were considered event free until death. The data of all patients were consecutively registered in the database of the Lower Austrian Myocardial Infarction Network. Individual patient data were handled in a blinded fashion, and the registry was performed according to the Helsinki criteria. The preclinical data were noted in an established STEMI record by the emergency physician on duty. The data from the preclinical records, as well as from the clinical records, were transferred into the MI network database.
Data Collection and Analysis
Analysis of data with regard to outcome parameters and protocol adherence were performed by two physicians (a cardiologist and an emergency physician) blinded to treatment. Normal distributed continuous data were reported as mean ± sd, and not normally distributed continuous data were reported as quartiles, minimum, and maximum. Categorical variables were compared using the chi-square and Fisher's exact test, where appropriate. Normal distributed continuous variables were compared using the Student t test. Nonparametric Mann-Whitney U tests were conducted to compare not normally distributed parameters.
Cardiovascular death, stroke, re-infarction in follow-up, and the need for revascularization in follow-up were defined as major cardiac adverse events (MACE).
Multivariable regression analyses were performed using Cox proportional hazard models to compare survival outcomes in patients with and without β-blocker treatment. Adjustment was performed for early β-blocker treatment, Clopidogrel and Metoprolol in Myocardial Infarction Trial shock index greater than or equal to 2 (including age greater than 70 yr, symptoms more than 12 hr, systolic blood pressure less than 120 mm Hg, and heart rate greater than 110 bpm), treatment only with drug-eluting stent, history of MI and/or PCI, and number of cardiovascular risk factors greater than or equal to 2 (including hypertension, diabetes, dyslipidemia, current smoking, family history of coronary artery disease). Kaplan-Meier survival curves using the log rank test were calculated for survival with and without β-blocker therapy. In order to reduce potential bias (e.g., potential advantage in survival of patients who received delayed β-blocker treatment), only patients who survived the first 48 hours were counted for survival analyses. A p value less than 0.05 for two-sided comparisons was considered statistically significant.
Statistical analyses with impact on main results were verified by a statistician of the Institute of Biostatistics and Clinical Research, University of Münster, Germany. Analyses were performed using the statistical software package IBM SPSS Statistics 20 (IBM Corporation, Armonk, NY).
RESULTS
General Characteristics
In total, 664 patients with STEMI were analyzed; 52% (n = 343) received immediate β-blocker treatment and 48% (n = 321) received a delayed β-blockade. About 38 patients had to be excluded due to lack of any β-blocker therapy (n = 21) or the administration of β-blocker (n = 17) at a time point which was not in accordance to the treatment protocol. Reasons for the lack of β-blocker or out-of-protocol treatment were cardiac arrest prior to application (n = 4), signs of cardiogenic shock (n = 3), prolonged hypotension (n = 9), bradycardia with the need to intervention (n = 8), unconsciousness of the patient (n = 2), vomiting (n = 9), lack of adherence to the protocol by the physician on duty (n = 3). Three patients were treated for recurrent infarction within the observational period. Only the first MI was counted for survival.
The baseline characteristics of all patients included in the study, as well as the characteristics of the patients counted for survival analyses, are illustrated in Table 1 . Except for age, no differences were observed between both treatment groups. Systolic and diastolic blood pressures and heart rate were significantly higher in patients treated with β-blocker ( Table 1) . The different time intervals, reperfusion strategies, number of affected coronary vessels, number of stents implanted, and the percentage of drug-eluting stents did not differ between the both treatment groups ( Table 2 ). The application of the β-blocker was done within the time interval of first ECG and departure from the site of operation. The average time interval was 12 minutes with a 95% confidence interval (CI) of 8.4-16.6 minutes in the early β-blocker group. The time interval between first ECG and departure was 11 minutes (95% CI, 7.6-16.3 min).
Mortality Data
The follow-up duration was 31 months (interquartile range: 8-44 months). When analyzing only patients within survival analyses, the probability of a fatal event was 19.2% in the group of patients with delayed β-blocker therapy and 10.7% in the group with immediate β-blocker therapy ( Table 3 ). The cardiovascular mortality after 30 days and after 1 year was lower in the immediate β-blocker treatment group (30-day cardiovascular mortality: immediate β-blocker: 0.9%; delayed β-blocker: 4.3%, p = 0.0058; 1-year cardiovascular mortality: immediate β-blocker: 1.9% delayed β-blocker: 8.1%, p = 0.0003; Table 3 ). Figure 1 shows the probability of survival starting 48 hours after first ECG. Log-rank test revealed a significant lower probability of death in patients with early β-blocker treatment (p < 0.001; Fig. 1 ). Analysing all-cause mortality with regard to different reperfusion strategies, the decrease of mortality of the immediate β-blocker group was consistent in the group of patients who were treated with primary PCI (delayed β-blocker treatment: n = 25, immediate β-blocker treatment: n = 12; p = 0.009). No significant differences of all-cause mortality were observed in the other groups (delayed β-blockade vs. immediate β-blockade: no intervention: 7 vs. 2 patients, p = 0.067; thrombolysis: 9 vs. 5 patients, p = not significant [NS]; coronary artery bypass graft: 0 vs. 2 patients, p = NS) The use of immediate β-blocker therapy was not associated with an increase of all-cause mortality in patients with an increased risk for cardiogenic shock (shock criteria ≥ 2; p = NS, Fig. 2) . In patients older than 70 years, survival was not different in this patient group with or without immediate β-blocker therapy (log-rank 0.23). Overall 24 patients (15 males, 57%; mean age 75 ± 9 years [median 78; range 61-88]) died within the first 48 hours after the first ECG (immediate β-blocker group: 5, delayed β-blocker group: 19). All patients died related to the MI.
Major Adverse Cardiovascular Events
The number of any major cardiac adverse events was significantly lower in patients with immediate β-blocker therapy compared with those with a delayed β-blocker therapy (immediate β-blocker group: 52; delayed β-blocker group: 71; p = 0.01; Table 4 ). The percentage of cardiovascular death was significantly lower in the immediate β-blocker group (2.9%) compared with the delayed β-blocker group (9.2%), but there were no significant differences between both groups concerning reinfarction, the need for revascularization, and for stroke within the observational period (Table 4) . Table 5 summarizes the average length of stay and the drug therapy of both groups at the time of discharge from the hospital. Analysis included the percentage of patients with aspirin, clopidogrel, statin therapy and renin-angiotensin-system blockade. No significant differences were observed between both groups. The discharge dose of bisoprolol was nearly identical between both groups. Figure 3 illustrates the frequency of STEMI-related complications within the first 24 hours after MI. The percentage of congestive heart failure (Killip class III or IV), cardiogenic shock, and ventricular fibrillation was not significantly different between both groups. Hypotensive episodes and bradycardia were more frequently noted in patients with a delayed β-blocker treatment (17 vs. 5, p = 0.008; 41 vs. 14, p < 0.001).
Discharge Data
Safety Parameters
Multivariable Survival Analysis
After adjustment for early β-blocker treatment, COMMIT-shock index ≥ 2 (including age > 70 yr, symptoms > 12 hr, systolic blood pressure < 120 mm Hg, heart rate > 110 bpm), treatment only with drug-eluting stent, number of cardiovascular risk factors greater than or equal to 2 (including arterial hypertension, diabetes, dyslipidemia, current smoking, family history of CAD), and history of MI and/or PCI, multivariable Cox regression analysis revealed a COMMIT shock index greater than or equal to 2 and history of MI and/or PCI as predictors for death of any cause ( 
DISCUSSION
Although treatment with β-blocker improves long-term outcomes in patients with acute MI, the beneficial effect of immediate or early treatment in the acute phase of STEMI is unclear. The question whether early β-blocker treatment is helpful or harmful is not answered yet. The COMMIT trial found that intravenous followed by oral metoprolol was harmful during the initial 24 hours with a significant increase in the risk of shock (6) . However, the applicability of this trial to European or North American practice is limited, as patients with PCI were excluded and 54% were treated with thrombolysis. Due to the combination of the primary use of an intravenous β-blocker formulation and completely different reperfusion strategies, it seems difficult to apply these data for recommendations in a complete different setting. In contrast, Yusuf et al (7) demonstrated a significant reduction of mortality if β-blockers were used early in the treatment of acute MI. Similar results from a German MI registry have been recently published (8) . The authors demonstrated a significant decrease in hospital mortality in patients with STEMI with and without reperfusion therapy. The benefit was even greater in high-risk patients with STEMI such as elderly patients and patients without reperfusion therapy. However, acute β-blocker therapy was defined within a maximum time range of 48 hours. In contrast, a recently published analysis of the data of the NCDR Action Registry-GWTG demonstrated that in high-risk patients for shock β-blocker therapy resulted in an increased number of patients with shock or death (4). However, this analysis included STEMI and NSTEMI patients, and the early use of β-blocker was defined as within the first 24 hours after acute MI. Therefore, it remains unanswered whether immediate β-blocker treatment may be helpful for patients with STEMI. To our knowledge, our analysis is the first comparing the immediate use of β-blockers (i.e., within 30 min after diagnosis of STEMI was confirmed by ECG out of hospital) with an administration of β-blockers after the first day of STEMI. We found a significant association between the immediate β-blocker treatment and all-cause mortality in the multivariate regression analysis. The reduction of mortality remained until 1 year after the acute event and included not only all-cause mortality but also cardiovascular mortality. The decrease was most pronounced in the primary PCI group. An important cause of concern using β-blocker is the possible development of serious complications such as congestive heart failure, bradyarrythmia, or even more important cardiogenic shock. However, the rate of complications such as heart failure or cardiogenic shock did not increase in patients with immediate β-blocker therapy during our observational study. These findings demonstrate the safe use of β-blockers in the outof-hospital setting if the contraindications were carefully considered. The subgroup analysis of patients with an increased risk for shock (possible shock criteria ≥2) illustrates that immediate β-blocker therapy had no adverse effect on the rate of cardiogenic shock. Even in patients older than 70 years, the immediate use of β-blockers was not associated with an adverse. These findings are especially important for the emergency services, as it demonstrates the safety of immediate use of β-blockers in patients with STEMI.
We assume that the timing of β-blocker administration in patients with STEMI is crucial with regard to a possible benefit on mortality. Beta-blockers reduce the heart rate and left ventricular work load with the result of a lower oxygen demand of the myocardium (9). The effect becomes even more important if the myocardium is ischemic. Due to these favorable effects, the immediate use of β-blockers may lead to a less widespread infarction (10) . Our results are consistent with data from a previous study, which demonstrated a reduced rate of reinfarction and recurrent chest pain in STEMI patients receiving intravenous metoprolol 2 hours after the diagnosis (11). However, this study was performed in the thrombolytic era and may be therefore not representative for the current STEMI management. Another more recent study investigated the use of β-blocker prior to primary coronary angioplasty in patients with acute MI (12). The probability of 1-year all-cause mortality of 3.2% in this previous study was identical to the mortality of 3.2% in our group of patients receiving β-blocker therapy immediately. The discrepancy to other previously published data demonstrating a harmful effect of β-blocker therapy may be explained by the different timing of β-blocker administration. If β-blockers are given as early as possible, the protective effect on the ischemic myocardium may be the crucial cause for the reduced mortality in patients with STEMI. In contrast, a delayed administration of β-blockers may have no effect on infarct size, as the necrosis has been determined especially if β-blockers are given later than 12 hours after the acute event. In these patients, the adverse hemodynamic effects may outweigh the beneficial effects of β-blocker therapy and may lead to hypotension, congestive heart failure, and cardiogenic shock. These potential complications have a negative effect of shortand long-term mortality in STEMI patients. Our assumptions are in line with previously published data of Sharma et al (13) , who demonstrated a significantly smaller elevation of creatine-kinase-muscle-brain after primary angioplasty in patients receiving β-blockers prior to the procedure compared with those receiving no β-blocker treatment. These data have been recently confirmed by experimental data demonstrating a larger myocardial salvage if intravenous metoprolol was given prior to coronary reperfusion (14) . Further recently ongoing studies such as the METOCARD-CNIC trial may provide further confirmation that the application of β-blockers prior to reperfusion may be associated with reduced infarct size and better prognosis of STEMI patients (15) .
Limitations
Despite these favorable data of imme diate β-blocker administration in STEMI patients, some caveats of our study have to be mentioned. As the design of the study is observational, some selection effects by confounders have to be taken into account. To reduce the bias due to possible confounders, we decided to exclude patients from survival analyses who died within 48 hours. The decision was made to ensure comparability of the different patients groups. The assumption is that patients dying within the first 48 hours have died independently of immediate or delayed β-blocker treatment, e.g., death occurred prior to a sufficient β-blocker effect. However, our data demonstrate clearly that the excluded patients exhibited similar general characteristics and vascular risk factors as the analyzed group of STEMI patients. Even the inclusion of these early died patients did not change the favorable effect of immediate β-blocker treatment on survival of STEMI patients. Therefore, the results of our study seem to be representative for patients with STEMI receiving β-blocker treatment. A second limitation is the lack of the exact time point of the β-blocker application in the outof-hospital setting. However, by analyzing the out-of-hospital recordings, we could determine two undisputable time points, that is, the writing of the first ECG and the time of departure from the site of operation. As drug treatment is usually done prior to departure, a very tight time frame could be identified within β-blockade was established. The mean time interval between first ECG and β-blocker application was at least within 12 minutes and 95% of all patients received the β-blocker within a time range between 8 and 16 minutes. As the time frame is very small, the observed differences of the β-blocker application should not have a considerable effect on the outcome parameters.
CONCLUSION
In summary, immediate β-blocker administration in the emergency setting of the Lower Austrian Myocardial Infarction Network seems to be associated with a reduction of all-cause and cardiovascular mortality in patients with STEMI. Immediate β-blocker administration could be superior to a delayed β-blockade in these patients with acute STEMI. Our data confirm the recommendations concerning the use of β-blockers in patients with acute MI. The establishment of β-blockade should be an essential part of the emergency treatment of patients with STEMI in the out-of-hospital setting, as the benefit seems to outweigh potential complications of β-blockers in our patient cohort. The findings of our study should be confirmed in a prospective randomized controlled trial.
